Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2025-12-26 @ 12:27 AM
Study NCT ID:
NCT03441360
Status:
COMPLETED
Last Update Posted:
2022-10-05
First Post:
2018-02-15
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Sponsor:
Eisai Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-04-17
Start Date Type:
ACTUAL
Primary Completion Date:
2021-01-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-01-21
Completion Date Type:
ACTUAL
First Submit Date:
2018-02-15
First Submit QC Date:
None
Study First Post Date:
2018-02-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-12-08
Results First Submit QC Date:
None
Results First Post Date:
2022-01-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-09-07
Last Update Post Date:
2022-10-05
Last Update Post Date Type:
ACTUAL